Analyst Price Target is $24.00
▲ +109.61% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kiniksa Pharmaceuticals in the last 3 months. The average price target is $24.00, with a high forecast of $24.00 and a low forecast of $24.00. The average price target represents a 109.61% upside from the last price of $11.45.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Kiniksa Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.